Catalyst Pharmaceutical Partners Inc. (Nasdaq:CPRX) announced its financial and operational results for the third quarter and nine months ended September 30, 2010. The Company reported a net loss of $903,985, or $0.05 per basic and diluted share compared to a net loss of $1,286,720, or $0.09 per basic and diluted share, for the same period in 2009. For the nine months ended September 30, 2010, the Company reported a net loss of $3,277,569, or $0.18 loss per basic and diluted share, compared to a net loss of $6,079,808, or $0.43 loss per basic and diluted share, for the same period in 2009.
Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders.
SavWatt USA, Inc. (SAVW.PK)
SavWatt USA, Inc., pioneers in LED lighting and the Green revolution, announced recently that SAVW’s first product has been approved and received Lighting Facts Certification by the U.S. Department of Energy. As innovative LED lighting products emerge, the facts about LED lighting performance must hit the market with equal speed. Clear labeling on lighting performance is the critical link between innovation and successful market introduction. Lighting Facts showcases LED luminaire manufacturers who commit to testing products and reporting performance results according to industry standards. For lighting buyers, designers, and energy efficiency programs, the Lighting Facts label provides information essential to evaluating products and identifying the best options.
Michael Haug, CEO of SAVW, commented, “This is a proud and exciting moment for SavWatt, having Lighting Facts certification means we are one of the few companies that meet the U.S. Department of Energy standards. This endorsement means SavWatt’s Brand has the quality and performance American consumers demand.”
SavWatt USA, Inc. is leading the LED lighting revolution and setting the stage to obsolete the incandescent light bulb through the use of energy-efficient, environmentally friendly LED lighting. SAVW is a market-leading innovator of LED lighting. SAVW’s product families include LED fixtures, bulbs, Street Lights and Parking Lights. To hear Recorder updates on the company Text SAVW to 46800.
To learn more about SAVW visit: http://www.savwatt.com
Zalicus Inc. (Nasdaq:ZLCS) reported financial results for the third quarter ended September 30, 2010. “We made solid product development progress this quarter,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “We finalized our development plans for Synavive, and also related to Synavive, we were awarded a Therapeutic Discovery Project grant to help fund Synavive development going forward. Our most promising Ion channel leads are in preclinical development with the goal of moving one or more into clinical development for pain in early 2011. And finally, the power of our combination high throughput discovery platform to generate potentially interesting oncology leads was highlighted at two oncology research meetings this Fall, further supporting the value of employing a systematic combination screening approach to identify novel product candidates.”
Zalicus Inc., a biopharmaceutical company, engages in the development of drug candidates focusing on the treatment of pain and inflammation. The company's clinical and preclinical product candidates for pain, inflammation, and other central nervous system disorders include Synavive (CRx-102), a novel dissociated glucocorticoid product candidate, which has completed Phase II clinical trials in subjects with knee osteoarthritis, to treat immuno-inflammatory disorders; Prednisporin (FOV1101), a topical ophthalmic drug candidate containing low doses of the glucocorticoid prednisolone acetate and the immunosuppressant cyclosporine A; N-type and T-type calcium channel blockers for the treatment of chronic pain; and CRx-601, a formulation of carbidopa and levodopa for the treatment of Parkinson?s disease.
Hiru Corporation’s (PINK SHEETS:HIRU) Shuangshi AHP Co.’s sales department recently held a large-scale product promotion fair.
Shuangshi AHP Co.’s sales department held a large-scale product promotion fair to present its customers the opportunity to review the full roster of Shuangshi AHP Co.’s animal health products and offer the sales force the opportunity to connect and create closer ties with their customers.
The fair attracted many people, with many customers placing orders right on the spot. The total order amount generated about 300,000 Yuan (approximately $45,000 USD) by the end of the fair.
Hiru Corporation and its main subsidiary Jiangxi Shuangshi Animal Health Products Co. (Shuangshi AHP Co.) focus on the development, manufacturing and marketing of a broad range of veterinary products for the Chinese Agricultural market. The company has established a strong position in the Chinese animal husbandry market and plans to expand and deliver more new products and solutions to this market in the future.
Hiru is pleased with the promotion and the new business that it initiated.
The company intends to make a series of updates and news announcements shortly on a more intense basis as its production and expansion plans progress
Hiru Corporation intends to continue its work in the development, production and marketing of both well-established and new veterinary drugs, and nutritional additives (amino acids, vitamins, trace elements, etc.) for the Chinese market.
The company is pleased with this development and looks forward to future growth.
Visit HIRU's website at: www.hirucorporation.com
Hampton Roads Bankshares Inc. (Nasdaq:HMPR) the holding company for Bank of Hampton Roads and Shore Bank, announced that it received a letter (the "Notification Letter") from The NASDAQ Stock Market ("NASDAQ") notifying the Company that it no longer meets NASDAQ's continued listing requirement under Listing Rule 5450(a)(1) (the "Bid Price Rule"). The Notification Letter states that the minimum bid price of the Company's common stock has traded below $1.00 per share for 30 consecutive business days and that the Company is therefore not in compliance with the Bid Price Rule.
Hampton Roads Bankshares, Inc. operates as the holding company for Bank of Hampton Roads (BOHR) and Shore Bank that provide community and commercial banking services primarily to individuals and businesses.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold BestOTC.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Hiru Corporation (HIRU.PK). Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for SavWatt USA, Inc. (SAVW.PK).